Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 696,313
  • Shares Outstanding, K 167,383
  • Annual Sales, $ 25,550 K
  • Annual Income, $ -341,970 K
  • EBIT $ -357 M
  • EBITDA $ -362 M
  • 60-Month Beta 1.59
  • Price/Sales 27.91
  • Price/Cash Flow N/A
  • Price/Book 0.85

Options Overview Details

View History
  • Implied Volatility 254.24% ( +52.53%)
  • Historical Volatility 66.49%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 254.24% on 12/20/24
  • IV Low 34.23% on 05/30/24
  • Put/Call Vol Ratio 0.48
  • Today's Volume 40
  • Volume Avg (30-Day) 375
  • Put/Call OI Ratio 1.62
  • Today's Open Interest 28,211
  • Open Int (30-Day) 51,131

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.59
  • Number of Estimates 8
  • High Estimate -0.39
  • Low Estimate -0.71
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +11.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.11 +1.22%
on 12/18/24
5.17 -19.54%
on 12/12/24
-0.50 (-10.73%)
since 11/20/24
3-Month
4.11 +1.22%
on 12/18/24
7.62 -45.42%
on 09/27/24
-3.34 (-44.53%)
since 09/20/24
52-Week
4.11 +1.22%
on 12/18/24
12.14 -65.73%
on 01/08/24
-6.35 (-60.42%)
since 12/20/23

Most Recent Stories

More News
Relay Therapeutics Reports Promising Interim Data for RLY-2608 in 2L PI3Kα-Mutated Metastatic Breast Cancer

Relay Therapeutics reports positive interim data for RLY-2608 in metastatic breast cancer, supporting a pivotal study in 2025.Quiver AI SummaryRelay Therapeutics, Inc. has announced updated interim clinical...

RLAY : 4.16 (-2.35%)
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

RLAY : 4.16 (-2.35%)
Relay Therapeutics to Present Updated Clinical Data for RLY-2608 at San Antonio Breast Cancer Symposium

Relay Therapeutics will present updated clinical data for RLY-2608 in advanced breast cancer at the San Antonio Symposium.Quiver AI SummaryRelay Therapeutics, a clinical-stage precision medicine company,...

RLAY : 4.16 (-2.35%)
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

RLAY : 4.16 (-2.35%)
Relay Therapeutics and Elevar Therapeutics Announce Global Licensing Agreement for Lirafugratinib, a Potential Best-in-Class FGFR2 Inhibitor

Elevar Therapeutics secures global rights to develop lirafugratinib, a promising FGFR2 inhibitor, with potential milestone payments for Relay Therapeutics.Quiver AI SummaryRelay Therapeutics and Elevar...

RLAY : 4.16 (-2.35%)
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

RLAY : 4.16 (-2.35%)
Relay Therapeutics to Participate in Upcoming Investor Conferences

RLAY : 4.16 (-2.35%)
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

RLAY : 4.16 (-2.35%)
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

RLAY : 4.16 (-2.35%)
Why Relay Therapeutics Plummeted by Nearly 14% Today

Investors weren't happy with the company's latest effort at capital-raising.

GS : 566.10 (+2.19%)
BAC : 44.17 (+1.82%)
SF : 104.49 (+2.17%)
RLAY : 4.16 (-2.35%)

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 4.43
2nd Resistance Point 4.37
1st Resistance Point 4.27
Last Price 4.16
1st Support Level 4.10
2nd Support Level 4.04
3rd Support Level 3.94

See More

52-Week High 12.14
Fibonacci 61.8% 9.07
Fibonacci 50% 8.13
Fibonacci 38.2% 7.18
Last Price 4.16
52-Week Low 4.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar